Home - Products - PI3K/Akt/mTOR signaling - PI3K - Zandelisib

Zandelisib

CAS No. 1401436-95-0

Zandelisib( ME-401 | PWT-143 )

Catalog No. M26519 CAS No. 1401436-95-0

Zandelisib is an inhibitor of phosphatidylinositol 3-kinase (PI3K)(p110δ, IC50 of 3.5 nM), and with antineoplastic activity.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
1 mL x 10 mM in DMSO	225	In Stock
5MG	178	In Stock
10MG	278	In Stock
25MG	487	In Stock
50MG	641	In Stock
100MG	882	In Stock
200MG	Get Quote	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Zandelisib
Note

Research use only, not for human use.
Brief Description

Zandelisib is an inhibitor of phosphatidylinositol 3-kinase (PI3K)(p110δ, IC50 of 3.5 nM), and with antineoplastic activity.
Description

Zandelisib is an inhibitor of phosphatidylinositol 3-kinase (PI3K)(p110δ, IC50 of 3.5 nM), and with antineoplastic activity.(In Vitro):Zandelisib inhibits PI3Ks(p110α, p110β, p110γ and p110δ with IC50s of 4, 976 nM, 605 nM, 817 nM and 3.5 nM, respectivey).
In Vitro

——
In Vivo

——
Synonyms

ME-401 | PWT-143
Pathway

PI3K/Akt/mTOR signaling
Target

PI3K
Recptor

Apoptosis
Research Area

——
Indication

——

Chemical Information

CAS Number

1401436-95-0
Formula Weight

576.697
Molecular Formula

C31H38F2N8O
Purity

>98% (HPLC)
Solubility

In Vitro:?DMSO : 33.33 mg/mL (57.80 mM)
SMILES

CN1CCC(CC1)c1ccccc1CC(C)(C)Nc1nc(nc(n1)-n1c(nc2ccccc12)C(F)F)N1CCOCC1
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1.Llado V, et al. Minerval induces apoptosis in Jurkat and other cancer cells. J Cell Mol Med. 2010 Mar;14(3):659-70.

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

mTOR inhibitor 9d

mTOR inhibitor 9d is a dual inhibitor of the protein kinases mTOR and PI3K with an mTOR IC50 value of 0.31 nm, and can be used for the treatment of leukemia, skin cancer, breast cancer, lung cancer and colon cancer.
LY294002

A classic, broad-spectrum PI3K inhibitor with IC50 of 0.5/0.57/0.97 uM for PI3Kα/δ/β, respectively.
Umbralisib

Umbralisib (RP5264,TGR1202, TGR-1202) is a potent, selective, orally available PI3Kδ inhibitor with IC50 of 22 nM.

Sign In Join Free